Open

AL Amyloidosis in Smoldering Multiple Myeloma Study

In this study, we want to see if certain genes are linked to a condition called AL amyloidosis. We want to see if these genes increase the risk of developing the condition in people with Smoldering Multiple Myeloma (SMM).

Age & Gender

40 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

North Carolina (Statewide)

What will be asked of you

You will be asked to provide a one-time-only liquid bone marrow during your bone marrow procedure, and a peripheral blood draw. The study will also collect data from your medical records throughout your participation.

Total length of participation:
5 years

Looking for Specific Volunteers

Able to participate:

You have been diagnosed with Smoldering Multiple Myeloma.
You have a dFLC greater than 23 mg/L.
You have an abnormal K::lambda FLC ratio.

Not eligible if:

You have a previous finding of amyloid in other biopsies.

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Trials Office
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Secondary Visit Location

UNC Hospitals Hillsborough Campus
460 Waterstone Dr, Hillsborough, NC 27278, USA

Additional Study Information

Principal Investigator

Sascha Tuchman
LCCC - Clinical Trials

Study Type

Clinical or Medical
Observational

Study Topics

Blood Conditions
Cancer (Multiple Myeloma)

IRB Number

24-0743

ClinicalTrials.gov

NCT06365060

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.